Ozmosi | Aripiprazole Drug Profile

Product Description

Aripiprazole is a medication that works in the brain to treat schizophrenia. It is also known as a second generation antipsychotic (SGA) or atypical antipsychotic. Aripiprazole rebalances dopamine and serotonin to improve thinking, mood, and behavior. (Sourced from: https://www.nami.org/About-Mental-Illness/Treatments/Mental-Health-Medications/Types-of-Medication/Aripiprazole-(Abilify))

Mechanisms of Action: D2 Agonist, 5-HT1A Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Approved

Approved Indications: None

Known Adverse Events: None

Company: Otsuka
Company Location: NEW YORK NY 10271
Company CEO:
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Aripiprazole

Countries in Clinic: China, Korea, New Zealand, Unknown Location

Active Clinical Trial Count: 9

Recent & Upcoming Milestones

Highest Development Phases

Phase 3: Bipolar Disorder|Schizophrenia

Phase 2: Autism Spectrum Disorder|Dermatitis, Atopic

Trial ID	Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success	Latest Trial Update Date	Data Updated
CTR20201480	CTR20201480	P1	Completed	Schizophrenia	2023-08-17		2025-04-29	Patient Enrollment\|Primary Completion Date\|Start Date\|Study Completion Date\|Treatments\|Trial Status
2016-005111-40	2016-005111-40	P2	Active, not recruiting	Autism Spectrum Disorder	2017-08-14		2025-06-29	Primary Completion Date\|Start Date\|Study Completion Date\|Treatments\|Trial Status
ACTRN12621001096842p	2006-7041-83/hah	P2	Not yet recruiting	Dermatitis, Atopic	2023-07-20
NCT03423680	APOLLO	P3	Recruiting	Bipolar Disorder	2025-11-01	45%	2024-10-16	Primary Endpoints
CTR20170309	CTR20170309	P3	Recruiting	Schizophrenia	None		2025-04-29
CTR20243723	CTR20243723	P3	Active, not recruiting	Schizophrenia	None		2025-11-09	Patient Enrollment\|Start Date\|Treatments\|Trial Status
CTR20212366	CTR20212366	P1	Completed	Schizophrenia	2023-08-17		2025-04-29	Patient Enrollment\|Primary Completion Date\|Start Date\|Study Completion Date\|Treatments\|Trial Status
CTR20170437	CTR20170437	P1	Recruiting	Schizophrenia	None		2025-04-29	Patient Enrollment\|Treatments\|Trial Status
CTR20170432	CTR20170432	P1	Recruiting	Schizophrenia	None		2025-04-29	Patient Enrollment\|Treatments\|Trial Status

Recent News Events

Date	Type	Title
11/21/2025	News Article	Wolters Kluwer Adds UpToDate Lexidrug's Comprehensive Drug Information to GenAI-powered Clinical Decision Support, UpToDate Expert AI
11/11/2025	News Article	Lundbeck delivers 14% CER revenue growth, reflecting stronger momentum from Vyepti® and Rexulti® driven by additional investments
11/03/2025	News Article	DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer
10/08/2025	News Article	Emalex Biosciences' Expanded Access Program for Investigational Tourette Syndrome Drug Receives FDA Authorization

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions

Session Expiring Soon

Aripiprazole

Alternative Names: aripiprazole, abilify, opc-14597, abilify maintena, bms-337039, abilify maintena kit, ARIPIPRAZOL, aripiprazol Clinical Status: Inactive Latest Update: 2025-11-25 Latest Update Note: Clinical Trial Update